Delayed production of neutralizing antibodies correlates with fatal COVID-19

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Understanding COVID-19 immune responses is crucial for predicting disease outcomes.
• The precise role of antibody dynamics in COVID-19 severity and mortality requires further elucidation.

Purpose of the Study:

• To analyze humoral immune responses in COVID-19 patients with varying disease severity.
• To investigate the correlation between antibody profiles, disease progression, and mortality.

Main Methods:

• Longitudinal analysis of humoral immune responses in 229 COVID-19 patients.
• Quantification of anti-spike (S) IgG, anti-receptor-binding domain (RBD) IgG, and neutralizing antibodies (NAbs).
• Correlation of antibody levels and kinetics with clinical parameters, hospitalization length, and survival.

Main Results:

• High anti-S IgG levels correlated with disease severity and hospitalization duration, but this relationship was time-dependent.
• Deceased patients exhibited delayed, yet robust, anti-S IgG, anti-RBD IgG, and NAb responses compared to survivors.
• Delayed seroconversion kinetics in non-survivors was associated with impaired viral control.
• NAb generation within 14 days of disease onset was a key factor for recovery.

Conclusions:

• COVID-19 mortality is associated with delayed kinetics of neutralizing antibody production, not solely with antibody levels.
• The timing of seroconversion, particularly NAb generation, is a critical determinant of COVID-19 outcomes.
• Targeting the kinetics of antibody response may offer therapeutic strategies for severe COVID-19.